Published in Women's Health Weekly, December 31st, 2009
Blackwell says the combination targeted therapy gave patients more than a four-month survival advantage over those who took lapatinib alone. She says the findings may be the first step toward a chemotherapy-free future.
"This is the first time that a pair of targeted therapies has been shown to be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly